Andrea Ardizzoni, MD, PhD, University of Bologna, Bologna, Italy, discusses the results of the TREASURE trial (NCT04462276) which aimed to enhance the response to carboplatin/etoposide + atezolizumab in extensive disease small cell lung cancer (SCLC) by adding thoracic radiotherapy (TRT) after induction chemotherapy. Although TRT-immunotherapy combinations have not been the source of safety concerns in other trials, it was associated with more severe adverse events (SAEs) in TREASURE. SAE analysis did not indicate any new safety signal of atezolizumab or TRT and observed SAEs were not clearly tied to immunotherapy or TRT. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.